We are pleased to announce that Gulf Drug LLC has received official approval of its greenhouse gas (GHG) emissions reduction near-term targets from the Science Based Targets initiative (SBTi). This means that our climate targets have been independently verified to be aligned with what climate science says is necessary to limit global warming to 1.5°C.
The SBTi is a global partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI), and WWF. It ensures that corporate climate targets are aligned with the goals of the Paris Agreement and the latest climate science.
Under our approved targets:
Gulf Drug LLC commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2022 base year.
Gulf Drug LLC also commits to reduce absolute scope 3 GHG emissions 25.0% within the same timeframe
These commitments cover our direct operations, purchased electricity, and key value-chain activities such as logistics, suppliers, and waste management. This achievement reflects the work of many teams across the company — from operations and facilities to procurement, finance, and administration. From now on, our emissions will be measured and disclosed annually, and progress against these targets will be tracked as part of our corporate performance.
As part of this commitment, we will also publish regular Sustainability Reports that disclose our emissions, progress against targets, and the actions we are taking to decarbonize our business.
Reaching these goals will require continuous improvement, efficiency, and collaboration across all functions. More information on how teams can support our decarbonization journey will be shared over time.
Thank you for helping make this important milestone possible.
